Healthcare Biz Cheat Sheet: FDA Approves Johnson & Johnson Pediatric Drug, Mela Sciences Shares Jump 80%
Delcath Systems (NASDAQ:DCTH) is trading higher today following a weekend announcement that data form a Phase 3 trial of its chemosaturation system showed extended survival rates for patients with melanoma metastases in the liver.
Cleveland BioLabs (NASDAQ:CBLI) has announced that Russian investment firm Rusnano will spend up to $26 million over the next four years to help fund a new unit that will develop preclinical drug candidates.
Johnson & Johnson (NYSE:JNJ) has received FDA approval for using Remicade on pediatric patients with ulcerative colitis.
ImmunoGen (NASDAQ:IMGN) is trading higher on positive results for a clinical trial of Roche’s (PINK:RHHBY) T-DM1 breast cancer drug, for which ImmunoGen will collect royalties.
Ariad Pharmaceuticals (NASDAQ:ARIA) has announced positive long-term results for a Phase 1 trial of its leukemia treatment.
Mela Sciences (NASDAQ:MELA) shares have skyrocketed over 80% today on news that the FDA had issued an “approvable letter” for its medical devices that aims to help doctors more accurately diagnose melanoma.
Teva Pharmaceuticals (NASDAQ:TEVA) has announced the buyout of a partner’s interest in a joint venture in Japan for $150 million. The company expects that coming under full ownership of its Japanese operations will drive pharmaceutical sales higher.